News

Why Are We Failing Veterans Who Bravely Served Our Country?
November 23, 2022
0
Exacis Biotherapeutics Grants Eterna Therapeutics an Option to License Up to Four Allogeneic IPSC-Derived NK and T Cell Therapies
October 19, 2022
0
Oxeia Announces Positive Interim Results of Phase 2 Trial for OXE103 for the Treatment of Concussions
August 3, 2022
0
Genetic Engineering & Biotechnology News – Bitter Taste Receptors Represent a Therapeutic Sweet Spot
February 2, 2022
0
Aardvark Therapeutics, Inc., Announces the Initiation of Enrollment for Three Phase 2 Clinical Trials Of Oral ARD-101
February 2, 2022
0